{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:22:42Z","timestamp":1782516162002,"version":"3.54.5"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.leukres.2018.01.014","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T10:25:04Z","timestamp":1517394304000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["PD-1 \/PD-L1 checkpoint in hematological malignancies"],"prefix":"10.1016","volume":"67","author":[{"given":"O.","family":"Annibali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Crescenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Tomarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Avvisati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0005","first-page":"60","article-title":"Generation of affinity matured scFv antibodies against mouse neural cell adhesion molecule L1 by phage display","volume":"301","author":"Dong","year":"2003","journal-title":"Biochem. Biophys."},{"key":"10.1016\/j.leukres.2018.01.014_bib0010","doi-asserted-by":"crossref","first-page":"29244","DOI":"10.4161\/onci.29244","article-title":"Distinct immunological mechanisms of CTLA-4 and PD -1 blockade revealed by analyzing TCR usage in blood lymphocytes","volume":"3","author":"Robert","year":"2014","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.leukres.2018.01.014_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.leukres.2018.01.014_bib0020","first-page":"1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0025","first-page":"58","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","volume":"1865","author":"Xia","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"7528","key":"10.1016\/j.leukres.2018.01.014_bib0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.leukres.2018.01.014_bib0035","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.4049\/jimmunol.181.9.5842","article-title":"Cutting edge: IFN-\u03b3 enables APC to promote memory Th17 and abate Th1 cell development","volume":"181","author":"Kryczek","year":"2008","journal-title":"J. Immunol."},{"issue":"328","key":"10.1016\/j.leukres.2018.01.014_bib0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.leukres.2018.01.014_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"issue":"111","key":"10.1016\/j.leukres.2018.01.014_bib0055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00277-017-3176-6","article-title":"PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas","volume":"97","author":"Wang","year":"2018","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2018.01.014_bib0070","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"6","key":"10.1016\/j.leukres.2018.01.014_bib0075","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup","volume":"31","author":"Gordon","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.leukres.2018.01.014_bib0080","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","article-title":"Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without","volume":"29","author":"Borchmann","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0085","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V89.3.801","article-title":"High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University","volume":"89","author":"Horning","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0090","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2004-12-4689","article-title":"High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100\u202fpatients","volume":"106","author":"Lavoie","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2018.01.014_bib0095","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/annonc\/mdu387","article-title":"Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"25","author":"Gerrie","year":"2014","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2018.01.014_bib0100","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","article-title":"Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma","volume":"32","author":"Kewalramani","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.leukres.2018.01.014_bib0105","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0110","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ejh.12770","article-title":"Pembrolizumab in classical Hodgkin\u2019s lymphoma","volume":"97","author":"Maly","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.leukres.2018.01.014_bib0120","first-page":"914","article-title":"Checkpoint inhibition in hodgkin lymphoma: saving the best for last?","volume":"30","author":"Lin","year":"2016","journal-title":"Oncology (Willist. Park. NY)"},{"key":"10.1016\/j.leukres.2018.01.014_bib0125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(02)00142-6","article-title":"Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues","volume":"84","author":"Ishida","year":"2002","journal-title":"Immunol. Lett."},{"issue":"17","key":"10.1016\/j.leukres.2018.01.014_bib0135","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2018.01.014_bib0140","first-page":"2093","article-title":"B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.01.014_bib0150","first-page":"69","article-title":"Immune checkpoint blockade in hematologic malignancies","author":"Armand","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2018.01.014_bib0155","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin. Cancer"},{"key":"10.1016\/j.leukres.2018.01.014_bib0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum. Pathol."},{"issue":"23","key":"10.1016\/j.leukres.2018.01.014_bib0165","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"November(3)","key":"10.1016\/j.leukres.2018.01.014_bib0170","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/imm.12788","article-title":"PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017","volume":"152","author":"Jelinek","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.leukres.2018.01.014_bib0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejca.2017.08.014","article-title":"Challenges and perspectives in the immunotherapy of Hodgkin lymphoma","volume":"85","author":"Michot","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.leukres.2018.01.014_bib0180","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.leukres.2018.01.014_bib0190","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.leukres.2018.01.014_bib0195","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non?small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.01.014_bib0200","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood.V126.23.583.583","article-title":"Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA 209-039)","volume":"126","author":"Ansell","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2018.01.014_bib0205","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.leukres.2018.01.014_bib0210","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0215","first-page":"221","article-title":"PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Am. Soc. Hematol."},{"issue":"December(1)","key":"10.1016\/j.leukres.2018.01.014_bib0220","article-title":"PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Godfrey","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.leukres.2018.01.014_bib0225","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.V126.23.584.584","article-title":"PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment","volume":"126","author":"Armand","year":"2015","journal-title":"Blood"},{"issue":"April","key":"10.1016\/j.leukres.2018.01.014_bib0230","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2018.01.014_bib0235","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","article-title":"Classification of lymphoid neoplasms: the microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.leukres.2018.01.014_bib0245","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non\u2013Hodgkin Lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin. Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2018.01.014_bib0250","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3109\/10428194.2012.673228","article-title":"Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy","volume":"53","author":"Li","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0255","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00428-014-1615-5","article-title":"Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma","volume":"465","author":"Ahearne","year":"2014","journal-title":"Virchows Arch."},{"issue":"19","key":"10.1016\/j.leukres.2018.01.014_bib0260","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2011.06.004","article-title":"Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines","volume":"56","author":"Chen","year":"2011","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.leukres.2018.01.014_bib0270","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2018.01.014_bib0275","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with","volume":"38","author":"Shi","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0280","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1309\/AJCPFJWKQ6GTVQE6","article-title":"Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas","volume":"142","author":"Ohgami","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"23","key":"10.1016\/j.leukres.2018.01.014_bib0285","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"February(2)","key":"10.1016\/j.leukres.2018.01.014_bib0290","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0295","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2018.01.014_bib0300","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1\u2013positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0305","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.humpath.2010.08.015","article-title":"Follicular programmed death 1\u2013positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma","volume":"42","author":"Richendollar","year":"2011","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0310","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/PAI.0b013e31828ef1f7","article-title":"Utility of BCL2, PD1, and CD25 immunohistochemical expression in the diagnosis of T-cell lymphomas","volume":"22","author":"O\u2019Malley","year":"2014","journal-title":"Appl Immunohistochem. Mol. Morphol."},{"issue":"12","key":"10.1016\/j.leukres.2018.01.014_bib0315","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","article-title":"Differential expression of programmed death-1 (PD-1) in S\u00e9zary syndrome and mycosis fungoides","volume":"148","author":"\u00c7etin\u00f6zman","year":"2012","journal-title":"Arch. Dermatol."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0320","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2015-02-626754","article-title":"Mechanisms of PD-L1\/PD-1\u2013mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E\u03bc-TCL1 CLL mouse model","volume":"126","author":"McClanahan","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis. Mark."},{"issue":"7","key":"10.1016\/j.leukres.2018.01.014_bib0330","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.humpath.2007.11.012","article-title":"Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"39","author":"Xerri","year":"2008","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0335","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8\u202f+\u202fPD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0340","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2016.214","article-title":"The PD-1\/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia","volume":"31","author":"Qorraj","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2018.01.014_bib0345","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer"},{"issue":"33","key":"10.1016\/j.leukres.2018.01.014_bib0350","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell","volume":"31","author":"Armand","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0355","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2018.01.014_bib0360","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood.V124.21.291.291","article-title":"Preliminary results of a phase I study of nivolumab (BMS -936558) in patients with relapsed or refractory lymphoid malignancies","volume":"124","author":"Lesokhin","year":"2014","journal-title":"Blood"},{"issue":"128","key":"10.1016\/j.leukres.2018.01.014_bib0365","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood.V128.22.1865.1865","article-title":"Nivolumab induces remission in high-PD -L1 expressing aggressive B-non hodgkin lymphoma: a single center experience","author":"Bohl","year":"2016","journal-title":"Blood"},{"issue":"June(26)","key":"10.1016\/j.leukres.2018.01.014_bib0370","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"October(Suppl. 7)","key":"10.1016\/j.leukres.2018.01.014_bib0375","article-title":"Multiple myeloma","volume":"21","author":"Blad\u00e9","year":"2010","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2018.01.014_bib0380","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2018.01.014_bib0385","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2018.01.014_bib0390","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","article-title":"Proteasome inhibitors in multiple myeloma: 10\u202fyears later","volume":"120","author":"Moreau","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2018.01.014_bib0395","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/ajh.23234","article-title":"Lenalidomide in multiple myeloma: current status and future potential","volume":"87","author":"Quach","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0400","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-LI) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD 88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0405","first-page":"1133","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol. Blood"},{"issue":"10","key":"10.1016\/j.leukres.2018.01.014_bib0410","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD -1 presence in the tumor microenvironment and activity of PD -1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.01.014_bib0415","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.leukres.2016.09.008","article-title":"PD-1\/PD-L1 expression in extra-medullary lesions of multiple myeloma","volume":"49","author":"Crescenzi","year":"2016","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0420","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.leukres.2018.01.014_bib0425","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti\u2013PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2018.01.014_bib0430","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2018.01.014_bib0435","doi-asserted-by":"crossref","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 Expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0440","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2018.01.014_bib0445","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.leukres.2018.01.014_bib0450","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.4049\/jimmunol.1202005","article-title":"Programmed death receptor-1\/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma","volume":"190","author":"Kearl","year":"2013","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.leukres.2018.01.014_bib0455","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.leukres.2018.01.014_bib0460","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin. cancer"},{"key":"10.1016\/j.leukres.2018.01.014_bib0465","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and","author":"Mateos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.01.014_bib0470","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood.V126.23.506.506","article-title":"A phase II study of anti PD \u22121 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"126","author":"Badros","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.014_bib0475","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.V128.22.2119.2119","article-title":"Pembrolizumab in combination with pomalidomide and dexamethasone (PEMBRO\/POM\/DEX) for pomalidomide exposed relapsed or refractory multiple myeloma","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.01.014_bib0480","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw375.35","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase","author":"Palumbo","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2018.01.014_bib0485","article-title":"Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized","volume":"27","author":"Ocio","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0490","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0495","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0500","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14712598.2015.1051028","article-title":"Programmed death-1 checkpoint blockade in acute myeloid leukemia","volume":"15","author":"Sehgal","year":"2015","journal-title":"Expert Opin. B"},{"issue":"5","key":"10.1016\/j.leukres.2018.01.014_bib0505","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2018.01.014_bib0510","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0515","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2018.01.014_bib0520","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-017-3051-5","article-title":"PD-1 signaling and inhibition in AML and MDS","volume":"96","author":"Haroun","year":"2017","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2018.01.014_bib0525","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2018.01.014_bib0530","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00277-016-2915-4","article-title":"Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms","volume":"96","author":"Choi","year":"2017","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0535","first-page":"195","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kr\u00f6nig","year":"2014","journal-title":"Eur. J."},{"issue":"December(1)","key":"10.1016\/j.leukres.2018.01.014_bib0540","article-title":"Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia","volume":"10","author":"Zhu","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0545","first-page":"484","article-title":"PD-1\/PD-L1 blocking enhances CD33\/CD3-bispecific BiTE\u00ae antibody (AMG 330) mediated lysis of primary AML cells","volume":"30","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0550","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0555","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.leukres.2018.01.014_bib0560","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2018.01.014_bib0565","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2018.01.014_bib0570","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.immuni.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8+ T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2018.01.014_bib0575","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coi.2014.01.002","article-title":"Orchestrating immune check-point blockade for cancer immunotherapy in combinations","volume":"27","author":"Perez-Gracia","year":"2014","journal-title":"Opin. Immunol."},{"issue":"2","key":"10.1016\/j.leukres.2018.01.014_bib0580","first-page":"214","article-title":"T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment","volume":"25","author":"Crespo","year":"2013","journal-title":"Curr. Opin."},{"issue":"11","key":"10.1016\/j.leukres.2018.01.014_bib0585","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.leukres.2018.01.014_bib0590","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12254-016-0292-2","article-title":"PD-L1 testing, fit for routine evaluation? From a patholo gist\u2019s point of view","volume":"9","author":"Hutarew","year":"2016","journal-title":"memo-Mag. Eur. Med. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2018.01.014_bib0595","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD -L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"468","author":"Ilie","year":"2016","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.leukres.2018.01.014_bib0600","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5414\/NP300698","article-title":"PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)","volume":"33","author":"Berghoff","year":"2014","journal-title":"Clin. Neuropathol."},{"issue":"10","key":"10.1016\/j.leukres.2018.01.014_bib0605","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24485","article-title":"The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome","volume":"91","author":"Bledsoe","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2018.01.014_bib0610","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Arch."},{"issue":"11","key":"10.1016\/j.leukres.2018.01.014_bib0615","doi-asserted-by":"crossref","first-page":"e0166266","DOI":"10.1371\/journal.pone.0166266","article-title":"PD-L1 status in refractory lymphomas","volume":"11","author":"Vranic","year":"2016","journal-title":"PLoS One"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T13:40:08Z","timestamp":1603719608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618300201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":123,"alternative-id":["S0145212618300201"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.01.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-1 \/PD-L1 checkpoint in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}